Case Reports

Myopic surprise after uneventful phaco surgery in nanophthalmos due to malignant glaucoma

Case Report Details

First Author: I.Saelens BELGIUM

Co Author(s):    J. Van Calster                    

Abstract Details

Purpose:

To describe the successful management of malignant glaucoma after uneventful phaco surgery.

Setting:

Department of Ophthalmology, University Hospitals Leuven, Belgium

Report of Case:

A 60 years old man with high hypermetropia of +9.0 diopters (D) and very shallow anterior chamber depth (ACD) of 1.22mm (internal diameter, scheimpflug topography) underwent uneventful phaco surgery at his right eye. A 40 D SN60AT lens (Alcon) was implanted in the capsular bag. At day one after surgery, best-corrected visual acuity (BCVA) was 20/30 with -6.0D. Scheimpflug images showed an internal ACD of 1.77 mm. Intraocular pressure (IOP) was 14 mmHg. Cycloplegia was started. At week one after surgery, the IOP increased and the myopic shift remained. A full vitrectomy combined with iridectomy and zonulectomy was performed because of malignant glaucoma. After vitrectomy, the IOP normalized and the internal anterior depth increased to 3.35mm. BCVA measured 20/25 and the myopic shift was reduced to a spherical equivalent of -1.0D.

Conclusion/Take Home Message:

Postoperative management of phaco surgery in nanophthalmic eyes can be challenging.

Financial Disclosure:

... gains financially from competing product or procedure, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... is employed by a competing company, ... has significant investment interest in a company producing, developing or supplying product or procedure presented